摘要
银屑病是一种由免疫介导的慢性炎症性皮肤病,发病机理复杂,不易根治。除先天遗传性的因素外,银屑病的发病因素主要是获得性免疫系统及先天性免疫系统的功能紊乱。由各类免疫细胞调控形成的细胞因子免疫环路在银屑病发生和发展中发挥重要作用,其中IL-23/IL-17/IL-36免疫环路近年来备受关注。本文从树突状细胞活化与免疫失衡、树突状细胞源性的IL-23与Th17细胞分化、Th17细胞源性的IL-17与银屑病皮肤炎症、角质形成细胞源性的IL-36与正反馈环形成4个环节综述了IL-23/IL-17/IL-36免疫环路在银屑病发病和治疗中的研究进展。并从IL-23相关抑制剂、IL-17相关抑制剂及IL-36相关抑制剂3个方面分析了国内外IL-23/IL-17/IL-36免疫环路的靶向药物研究现状。最后提出同时针对IL-23/IL-17/IL-36免疫环路中的多靶点干预可能是下一代生物制剂开发的热点。为银屑病的发病机制研究及相关药物开发提供参考。
Psoriasis is a chronic inflammatory skin disease with a complex pathogenesis mediated by the dysfunction of immune system that is not easily curable.In addition to the factors of congenital and hereditary,the main pathogenic factors in the occurrence and development of psoriasis are a dysfunction of the acquired and innate immune systems.Cytokine immune loops formed by various types of immune cells play an important role in the occurrence and development of psoriasis,and the IL-23/IL-17/IL-36 immune loops have received much attention in recent years.This paper reviewed the research progress of the IL-23/IL-17/IL-36 immune loop in psoriasis from four perspectives:dendritic cell activation and immune imbalance,dendritic cell derived IL-23 and Th17 cell differentiation,Th17 cell derived IL-17 and psoriatic skin inflammation,and keratinocyte derived IL-36 and positive feedback loop formation.In addition,the current status of domestic and international research on targeted drugs in the IL-23/IL-17/IL-36 immune loop was analyzed from three aspects:IL-23 related inhibitors,IL-17 related inhibitors,and IL-36 related inhibitors.Finally,it has been suggested that simultaneous multi-target interventions targeting the IL-23/IL-17/IL-36 immune loop may be a hot area for the development of next-generation biologics.It serves as a reference for the pathogenesis of psoriasis and the development of related drugs.
作者
陈文城
王梦
肖紫丹
张进强
文昌晖
CHEN Wencheng;WANG Meng;XIAO Zidan;ZHANG Jinqiang;WEN Changhui(The First Clinical Medical College,Guizhou University of Traditional Chinese Medicine,Guiyang 550001,China;Guizhou University of Traditional Chinese Medicine,Guiyang 550025,China)
出处
《中国皮肤性病学杂志》
CAS
CSCD
北大核心
2024年第3期335-343,共9页
The Chinese Journal of Dermatovenereology
基金
国家自然科学基金项目(82060726)。
